Drug approval via the FDA's breakthrough therapy designation risks confusion.

Subjects

Subjects :

DRUG approval
COGNITION disorders
BIOMARKERS
DIRECT-to-consumer prescription drug advertising
INVESTIGATIONAL drugs
MEDICAL care costs
ADVERTISING
DRUG laws
INAPPROPRIATE prescribing (Medicine)
HEALTH care reform
DRUG development
PATIENT education
PATIENT-professional relations
LOBBYING

Details

Language :

English

ISSN :

17561833

Volume :

384

Issue :

8418

Database :

Complementary Index

Journal :

BMJ: British Medical Journal

Publication Type :

Academic Journal

Accession number :

175585395